NASDAQ:PFSA 29 October 2025 - 31 December 2025

Profusa’s after-hours surge came on the heels of a positive company update. The California-based digital health firm announced it has completed key manufacturing initiatives, creating enough production capacity to supply more than twice the units needed to meet its 2026 revenue goals for the Lumee™ continuous oxygen sensor systembenzinga.com. Fred Knechtel, Profusa’s CFO, said the team is “laser-focused on achieving revenue from sales of Lumee tissue oxygen monitoring systems… at the start of the second quarter of 2026,” with inventory shipments to distributors planned in Q1 2026benzinga.com. To support that timeline, Profusa finished the first full run of sensor production in October and even began production of its Lumee injector “pens,” according to the updatebenzinga.com.